Whitehawk Therapeutics Welcomes Dr. Margaret Dugan as Chief Medical Officer

In a significant move for the oncology therapeutics firm, Whitehawk Therapeutics, Inc. has announced the appointment of Dr. Margaret Dugan, MD, as their Chief Medical Officer (CMO). Based in Morristown, New Jersey, the company specializes in advanced technologies and antibody drug conjugates (ADCs) aimed at improving cancer treatment efficacy.

Dr. Dugan brings with her over 30 years of invaluable experience in global oncology drug development, coupled with a wealth of knowledge in early-stage clinical development and regulatory strategies. This unique combination of skills makes her a strategic addition to the Whitehawk team, especially as the company approaches a crucial phase in bringing its novel ADC programs to clinical practice.

"I am thrilled to welcome Margaret to Whitehawk," stated Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. He emphasized that Dr. Dugan's expertise and strategic vision will bolster the company’s ability to craft effective clinical studies and expedite the transition of their ADC portfolio into potential therapeutic solutions for patients battling cancer.

Prior to joining Whitehawk, Dr. Dugan held senior leadership positions in various organizations, where she achieved a series of remarkable milestones in oncology drug development. Throughout her career, she has successfully overseen more than 12 Phase 1 clinical trials and has been instrumental in securing regulatory approvals for vital oncology treatments—such as capmatinib and ceritinib—across several cancer types.

Notably, Dr. Dugan spent over 15 years at Novartis, where she established and led an innovative early development organization. Her efforts there included advancing projects from initial proof-of-concept through full clinical development, significantly contributing to global regulatory consent. Following her tenure at Novartis, Dr. Dugan served as CMO at Dracen Pharmaceuticals, successfully advancing their inaugural clinical program through Phase 1 and obtaining Fast Track designation from the FDA. Furthermore, at Schrödinger, she built the clinical function and pushed three Phase 1 assets into clinical trials, culminating in a program reaching Phase 2 readiness in a commendably short time.

Dr. Dugan commenced her career in academia as a medical oncologist and has smoothly transitioned into industry leadership roles. This unique perspective—as someone who understands the intricacies of both medical practice and corporate strategy—positions her exceptionally well to drive the clinical development of Whitehawk's innovative treatments.

Reflecting on her new role, Dr. Dugan expressed enthusiasm about joining Whitehawk Therapeutics at a pivotal juncture. "I am excited to engage with Whitehawk during this critical phase of clinical development. Our approach synergizes smart target selection and a distinct ADC profile, creating a significant opportunity to fulfill the potential of next-generation ADC therapies. I look forward to collaborating with this talented team to advance our portfolio, striving to make a meaningful difference for patients facing difficult-to-treat cancers," she stated.

Whitehawk Therapeutics is committed to transforming the landscape of cancer treatment. They are focusing on establishing a robust ADC portfolio designed to transcend the limitations of first-generation counterparts. The company has secured exclusive licenses for these innovative assets from WuXi Biologics, which includes comprehensive development and commercialization agreements.

As they move forward, Whitehawk Therapeutics would continue focusing on research and development strategies to ensure their place at the forefront of oncology therapeutics. The potential therapeutic benefits and market opportunities presented by their advanced ADC portfolio reflect a promising horizon for the company and the patients they aim to serve.

With Dr. Dugan at the helm of clinical strategy, stakeholders are optimistic about the future trajectories of Whitehawk Therapeutics and the enhancements they may bring to cancer care protocols. For more information about their advancements and initiatives, visit www.whitehawktx.com or connect with them on LinkedIn.